Repeated effects of asenapine on adrenergic and cholinergic muscarinic receptors

International Journal of Neuropsychopharmacology

Volumn 13, Issue 3, 2010, Pages 405-410

  Choi, Yong Kee ^a,b   Wong, Erik H F ^c   Henry, Brian ^d   Shahid, Mohammed ^e   Tarazi, Frank I ^a,b  

^a MASSACHUSETTS GENERAL HOSPITAL   (United States)

^b HARVARD MEDICAL SCHOOL   (United States)

^c ASTRAZENECA   (United Kingdom)

^d Schering Plough   (Singapore)

^e Schering Plough Research Institute   (United Kingdom)

Author keywords

Adrenergic receptors; Asenapine; Frontal cortex; Hippocampus; Muscarinic receptors

Indexed keywords

2 (2 METHOXY 1,4 BENZODIOXAN 2 YL) 2 IMIDAZOLINE; 2 (2 METHOXY 1,4 BENZODIOXAN 2 YL) 2 IMIDAZOLINE H 3; ADRENERGIC RECEPTOR; ALPHA 1 ADRENERGIC RECEPTOR; ALPHA 2 ADRENERGIC RECEPTOR; ASENAPINE; DRUG VEHICLE; MUSCARINIC M1 RECEPTOR; MUSCARINIC M2 RECEPTOR; MUSCARINIC M3 RECEPTOR; MUSCARINIC M4 RECEPTOR; MUSCARINIC M5 RECEPTOR; MUSCARINIC RECEPTOR; PRAZOSIN H 3; QUINUCLIDINYL BENZILATE; QUINUCLIDINYL BENZILATE H 3; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BIPOLAR DISORDER; CONTROLLED STUDY; DRUG RECEPTOR BINDING; DRUG SELECTIVITY; FOREBRAIN; HIPPOCAMPUS; MALE; NONHUMAN; PREFRONTAL CORTEX; PRIORITY JOURNAL; RAT; RECEPTOR AFFINITY; SCHIZOPHRENIA;

ADRENERGIC AGENTS; ANIMALS; ANTIPSYCHOTIC AGENTS; BINDING, COMPETITIVE; CHOLINERGIC AGENTS; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG ADMINISTRATION SCHEDULE; HETEROCYCLIC COMPOUNDS WITH 4 OR MORE RINGS; PROSENCEPHALON; PROTEIN BINDING; RADIOLIGAND ASSAY; RATS; RECEPTORS, ADRENERGIC; RECEPTORS, MUSCARINIC; TISSUE DISTRIBUTION; TRITIUM;

EID: 77953539184     PISSN: 14611457     EISSN: 14695111     Source Type: Journal    
DOI: 10.1017/S1461145709990824     Document Type: Article

References (29)

1. Araki T, Tanji H, Fujihara K, Kato H, et al. (2000). Sequential changes of cholinergic and dopaminergic receptors in brains after 6-hydroxydopamine lesions of the medial forebrain bundle in rats. Journal of Neural Transmission 107, 873-884.
2. Arnsten AF (2004). Adrenergic targets for the treatment of cognitive deficits in schizophrenia. Psychopharmacology 174, 25-31.
3. Baldessarini RJ, Tarazi FI (2005). Pharmacotherapy of psychosis and mania. In: Brunton LL, Lazo JS, Parker KL (Eds), Goodman and Gilman's The Pharmacological Basis of Therapeutics (pp. 461-500). New York, NY: McGraw-Hill.
4. Bylund DB, Eikenberg DC, Hieble JP, Langer SZ, et al. (1994). International Union of Pharmacology nomenclature of adrenoceptors. Pharmacological Reviews 46, 121-136.
5. Cahir M, Mawhinney T, King DJ (2004). Differential region-specific regulation of central alpha 1-adrenoceptor binding following chronic haloperidol and clozapine administration in the rat. Psychopharmacology 172, 196-201.
6. Chapel S, Hutmacher M, Haig G, Bockbrader H, et al. (in press). Exposure-response analysis in patients with schizophrenia to assess the effect of asenapine, quetiapine, or placebo administration on QTc prolongation. Journal of Clinical Pharmacology.
7. Dean B, Bymaster FP, Scarr E (2003). Muscarinic receptors in schizophrenia. Current Molecular Medicine 3, 419-426.
8. Franberg O, Wiker C, Marcus MM, Konradsson A, et al. (2008). Asenapine, a novel psychopharmacologic agent: preclinical evidence for clinical effects in schizophrenia. Psychopharmacology 196, 417-429.
9. Ghanbari R, El Mansari M, Shahid M, Blier P (2009). Electrophysiological characterization of the effects of asenapine at 5-HT(1A), 5-HT(2A), alpha(2)-adrenergic and D(2) receptors in the rat brain. European Neuropsycho-pharmacology 19, 177-187.
10. 3H]prazosin. Brain Research 672, 214-227.
11. Happe HK, Coulter CL, Gerety ME, Sanders JD, et al. (2004). Alpha-2 adrenergic receptor development in rat CNS: an autoradiographic study. Neuroscience 123, 167-178.
12. Hertel P, Fagerquist MV, Svensson TH (1999). Enhanced cortical dopamine output and antipsychotic-like effects of raclopride by alpha2 adrenoceptor blockade. Science 286, 105-107.
13. Huang M, Li Z, Dai J, Shahid M, Wong EH, Meltzer HY (2008). Asenapine increases dopamine, norepinephrine, and acetylcholine efflux in the rat medial prefrontal cortex and hippocampus. Neuropsychopharmacology 33, 2934-2945.
14. Hulme EC, Birdsall NJ, Buckley NJ (1990). Muscarinic receptor subtypes. Annual Review of Pharmacology and Toxicology 30, 633-673.
15. Ji XH, Ji JZ, Zhang H, Li BM (2008). Stimulation of alpha2-adrenoceptors suppresses excitatory synaptic transmission in the medial prefrontal cortex of rat. Neuropsychopharmacology 33, 2263-2271.
16. Marek GJ, Aghajanian GK (1999). 5-HT2A receptor or alpha1-adrenoceptor activation induces excitatory postsynaptic currents in layer V pyramidal cells of the medial prefrontal cortex. European Journal of Pharmacology 367, 197-206.
17. McIntyre R, Cohen M, Zhao J, Alphs L, et al. (in press). A 3-week, randomized and placebo-controlled trial of asenapine in the treatment of acute mania in bipolar disorder. Bipolar Disorders.
18. Paxinos G, Watson C (1982). The Rat Brain in Stereotaxic Coordinates. San Diego, CA: Academic Press.
19. Potkin SG, Cohen M, Panagides J (2007). Efficacy and tolerability of asenapine in acute schizophrenia: a placebo-and risperidone-controlled trial. Journal of Clinical Psychiatry 68, 1492-1500.
20. Richards MH (1991). Pharmacology and second messenger interactions of cloned muscarinic receptors. Biochemical Pharmacology 42, 1645-1653.
21. Scarr E, Dean B (2008). Muscarinic receptors: do they have a role in the pathology and treatment of schizophrenia? Journal of Neurochemistry 107, 1188-1195.
22. Shahid M, Walker G, Zorn S, Wong E (2009). Asenapine: a novel psychopharmacologic agent with a unique human receptor signature. Journal of Psychopharmacology 23, 65-73.
23. Svensson TH (2003). Alpha-adrenoceptor modulation hypothesis of antipsychotic atypicality. Progress in Neuro-Psychopharmacology and Biological Psychiatry 27, 1145-1158.
24. Tarazi FI, Choi YK, Gardner M, Wong EH, et al. (2009). Asenapine exerts distinctive regional effects on ionotropic glutamate receptor subtypes in rat brain. Synapse 63, 413-420.
25. Tarazi FI, Moran-Gates T, Wong EH, Henry B, Shahid M (in press). Asenapine induces differential regional effects on serotonin receptor subtypes. Journal of Psychopharmacology.
26. Tarazi FI, Moran-Gates T, Wong EH, Henry B, Shahid M (2008). Differential regional and dose-related effects of asenapine on dopamine receptor subtypes. Psychopharmacology 198, 103-111.
27. Terry Jr. AV, Gearhart DA, Mahadik SP, Warsi S, Waller JL (2006). Chronic treatment with first or second generation antipsychotics in rodents: effects on high affinity nicotinic and muscarinic acetylcholine receptors in the brain. Neuroscience 140, 1277-1287.
28. 4 muscarinic receptor knockout mice. Molecular Psychiatry 8, 673-679.
29. Winer BJ, Brown DR, Michels KM (1991). Statistical Principles in Experimental Design, 3rd edn (pp. 165-166). New York: McGraw Hill.